Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Opiant Pharmaceuticals, Inc. OPNT
$20.65
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
108798242.00000000
-
week52high
27.36
-
week52low
7.34
-
Revenue
40725185
-
P/E TTM
-3
-
Beta
0.83158900
-
EPS
-6.53000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 авг 2022 г. в 20:00
Описание компании
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Outperform | 09 дек 2021 г. | |
| Cantor Fitzgerald | Overweight | Overweight | 28 сент 2018 г. |
| Cantor Fitzgerald | Overweight | 12 июн 2018 г. | |
| B. Riley FBR | Neutral | Buy | 05 мая 2018 г. |
| Mizuho | Neutral | Buy | 30 ноя 2012 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| CRYSTAL ROGER | D | 75339 | 1358 | 27 янв 2023 г. |
| O'Toole David D | D | 34248 | 541 | 27 янв 2023 г. |
| Skolnick Phil | D | 21548 | 480 | 27 янв 2023 г. |
| Gorman Brian | D | 31990 | 444 | 27 янв 2023 г. |
| Ellison Mark Jason Heath | D | 18751 | 610 | 27 янв 2023 г. |
| O'Toole David D | D | 34789 | 415 | 09 янв 2023 г. |
| Ellison Mark Jason Heath | D | 19361 | 469 | 09 янв 2023 г. |
| CRYSTAL ROGER | D | 76697 | 1183 | 09 янв 2023 г. |
| Skolnick Phil | D | 22028 | 369 | 09 янв 2023 г. |
| Ellison Mark Jason Heath | D | 19830 | 1806 | 05 янв 2023 г. |
Новостная лента
What's The Opiant CVR Worth?
Seeking Alpha
11 февр 2023 г. в 03:50
Opiant appears on track to be acquired for $20/share and offers various Contingent Value Rights (CVRs) linked to a potential drug launch. The drug helps with opioid reversal after an overdose and has a scheduled FDA review date of May 2023.
Opiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown In
Seeking Alpha
13 янв 2023 г. в 14:26
I love to get a CVR during a takeover process. This happens a lot when pharma or biotech companies with important unapproved assets get bought.
Why Is Opiant Pharma (OPNT) Stock Up 116% Today?
InvestorPlace
14 ноя 2022 г. в 10:58
Opiant Pharmaceuticals (NASDAQ: OPNT ) stock is rocketing higher on Monday following news that Indivior is acquiring the Narcan maker! Indivior is offering to acquire shares of OPNT stock for $28 each.
Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022
GlobeNewsWire
27 окт 2022 г. в 16:05
SANTA MONICA, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the third quarter ended September 30, 2022, after the financial markets close on Monday, November 14, 2022.
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
12 авг 2022 г. в 09:10
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Ben Atkins - VP Communications and Investor Relations Roger Crystal - President, Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Carl Byrnes - Northland Capital Markets Trevor Allred - Oppenheimer Operator Greetings, and welcome to Opiant Pharmaceuticals Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.